On October 23, 2023, Mr. Tony Kalajian resigned from all positions in Calidi Biotherapeutics, Inc., including his roles as Chief Accounting Officer and as interim Chief Financial Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.236 USD | -4.88% | +4.52% | -84.37% |
04-16 | Calidi Biotherapeutics Prices $6.1 Million Offering | MT |
03-21 | H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-84.37% | 11.55M | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-2.36% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |
- Stock Market
- Equities
- CLDI Stock
- News Calidi Biotherapeutics, Inc.
- Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Interim Chief Financial Officer